Kura Oncology announced the appointment of Jennifer Fulk as the company's new Chief Financial Officer, principal financial officer, and principal accounting officer, effective September 8, 2026. Ms. Fulk joins the company with extensive experience from senior finance roles at Eli Lilly and Company, Talkspace, and Soleno Therapeutics.
Key Details
- Effective Date: The appointment is effective as of September 8, 2026.
- Compensation Package: Ms. Fulk's employment agreement includes an annual base salary of $550,000, an annual discretionary bonus target of up to 45% of her base salary, and significant equity awards.
- Equity Awards: The agreement grants an option to purchase 450,000 shares of common stock vesting over four years and a one-time performance-based restricted stock unit (PSU) award covering 173,438 shares tied to specific company milestones.
- Role Transition: Ms. Fulk replaces Troy E. Wilson as principal financial officer and Thomas Doyle as principal accounting officer.